Gujarat Themis Biosyn informs about commencement of commercial production

18 Oct 2025 Evaluate

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Gujarat Themis Biosyn has informed that the Company has completed the expansion of its Fermentation Block at its manufacturing facilities at Vapi, Gujarat. The first batch of commercial production of Rifamycin-S and Rifamycin-O has commenced today, Saturday, October 18, 2025. With this expansion, the overall fermentation capacity of the Company has increased from 450 KL to 990 KL. This will further strengthen the Company’s manufacturing capabilities to produce multiple fermentation products. With this capacity expansion, the Company is in a strong position to capitalise on the significant growth opportunities in the fermentation segment.

The above information is a part of company’s filings submitted to BSE. 

Guj. Themis Biosyn Share Price

377.65 -9.95 (-2.57%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×